Analyzing ophthalmic suspension particle size distributions using laser diffraction: Placebo background subtraction method

Nanobubble size distribution measurement by interactive force apparatus under an electric field

Nanobubbles have been applied in many fields, such as environmental cleaning, material production, agriculture, and medicine. However, the measured nanobubble sizes differed among the measurement methods, such as dynamic light scattering, particle trajectory, and resonance mass methods. Additionally, the measurement methods were limited with respect to the bubble concentration, refractive index of liquid, and liquid color. Here, a novel interactive force measurement method for bulk nanobubble size measurement was developed by measuring the force between two electrodes filled with bulk nanobubble-containing liquid under an electric field when the electrode distance was changed in the nm scale with piezoelectric equipment. The nanobubble size was measured with a bubble gas diameter and also an effective water thin film layer covered with a gas bubble that was estimated to be approximately 10 nm based on the difference between the median diameter of the particle trajectory method and this method. This method could also be applied to the solid particle size distribution measurement in a solution.

Advances in in-vitro bioequivalence testing methods for complex ophthalmic generic products

The United States Food and Drug Administration (USFDA) demands that the generic industry prove topical ocular products' pharmaceutical and bioequivalence (BE). In contrast to generic oral drugs, topical ocular product BE testing has proved difficult. New generic versions are compared to an authorized drug product known as a Reference Listed Drug (RLD) to demonstrate their bioequivalence. If the excellent in-vitro results may support the presumption of equivalence in-vivo performance and the only clinically significant difference between the generic and RLD is in its physicochemical qualities and drug release rate, then in-vivo BE studies may be waived. Proving BE through dissolution tests is a golden standard for most conventional dosage forms. However, due to the limited number of biorelevant in-vitro drug release testing (IVRT) approaches capable of differentiating their performance based on product quality and physicochemical properties, the development of generic ophthalmic products has been slow and time-consuming. Often, BE of topical ophthalmic formulations cannot be proved using a single in-vitro test; therefore, an elaborated discussion on various IVRT methods performed to demonstrate bioequivalence of complex generis like ophthalmic emulsions, suspensions, ointments, and gels is necessary. This manuscript aims to review the status of biowaiver criteria for complex ophthalmic products concerning the product-specific FDA guidance to the generic industry.